|
US2779780A
(en)
|
1955-03-01 |
1957-01-29 |
Du Pont |
1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
|
|
GB8827305D0
(en)
|
1988-11-23 |
1988-12-29 |
British Bio Technology |
Compounds
|
|
JP2861087B2
(ja)
|
1989-08-08 |
1999-02-24 |
三菱化学株式会社 |
N―アシル‐5‐ピラゾールカルボキサミド類およびこれを有効成分とする殺虫、殺ダニ剤
|
|
FI941572L
(fi)
|
1991-10-07 |
1994-05-27 |
Oncologix Inc |
Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
|
|
CA2372813A1
(en)
|
1992-02-06 |
1993-08-19 |
L.L. Houston |
Biosynthetic binding protein for cancer marker
|
|
IT1255527B
(it)
|
1992-09-29 |
1995-11-09 |
Mini Ricerca Scient Tecnolog |
Pirazolcarbossammidi ad attivita' insetticida ed acaricida
|
|
US6177401B1
(en)
|
1992-11-13 |
2001-01-23 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften |
Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
|
|
US5455258A
(en)
|
1993-01-06 |
1995-10-03 |
Ciba-Geigy Corporation |
Arylsulfonamido-substituted hydroxamic acids
|
|
EP0647450A1
(en)
|
1993-09-09 |
1995-04-12 |
BEHRINGWERKE Aktiengesellschaft |
Improved prodrugs for enzyme mediated activation
|
|
IL112248A0
(en)
|
1994-01-25 |
1995-03-30 |
Warner Lambert Co |
Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
|
|
US5863949A
(en)
|
1995-03-08 |
1999-01-26 |
Pfizer Inc |
Arylsulfonylamino hydroxamic acid derivatives
|
|
CA2218503C
(en)
|
1995-04-20 |
2001-07-24 |
Pfizer Inc. |
Arylsulfonyl hydroxamic acid derivatives
|
|
US5747498A
(en)
|
1996-05-28 |
1998-05-05 |
Pfizer Inc. |
Alkynyl and azido-substituted 4-anilinoquinazolines
|
|
US5880141A
(en)
|
1995-06-07 |
1999-03-09 |
Sugen, Inc. |
Benzylidene-Z-indoline compounds for the treatment of disease
|
|
GB9520822D0
(en)
|
1995-10-11 |
1995-12-13 |
Wellcome Found |
Therapeutically active compounds
|
|
GB9624482D0
(en)
|
1995-12-18 |
1997-01-15 |
Zeneca Phaema S A |
Chemical compounds
|
|
DK0780386T3
(da)
|
1995-12-20 |
2003-02-03 |
Hoffmann La Roche |
Matrixmetalloproteaseinhibitorer
|
|
NZ331191A
(en)
|
1996-03-05 |
2000-03-27 |
Zeneca Ltd |
4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
|
|
EP0818442A3
(en)
|
1996-07-12 |
1998-12-30 |
Pfizer Inc. |
Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
|
|
HRP970371A2
(en)
|
1996-07-13 |
1998-08-31 |
Kathryn Jane Smith |
Heterocyclic compounds
|
|
AR007855A1
(es)
|
1996-07-13 |
1999-11-24 |
Glaxo Group Ltd |
Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios, uso en medicinay composiciones farmaceuticas que los contienen
|
|
US6391874B1
(en)
|
1996-07-13 |
2002-05-21 |
Smithkline Beecham Corporation |
Fused heterocyclic compounds as protein tyrosine kinase inhibitors
|
|
EP0923585B1
(en)
|
1996-07-18 |
2002-05-08 |
Pfizer Inc. |
Phosphinate based inhibitors of matrix metalloproteases
|
|
EP0922030A1
(en)
|
1996-08-23 |
1999-06-16 |
Pfizer Inc. |
Arylsulfonylamino hydroxamic acid derivatives
|
|
ID18494A
(id)
|
1996-10-02 |
1998-04-16 |
Novartis Ag |
Turunan pirazola leburan dan proses pembuatannya
|
|
US6077864A
(en)
|
1997-01-06 |
2000-06-20 |
Pfizer Inc. |
Cyclic sulfone derivatives
|
|
HUP0000852A2
(hu)
|
1997-02-03 |
2001-05-28 |
Pfizer Products Inc. |
Aril-szulfonil-amino-hidroxámsav-származékok, valamint e vegyületeket tartalmazó gyógyászati készítmények
|
|
JP2000507975A
(ja)
|
1997-02-07 |
2000-06-27 |
ファイザー・インク |
N−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用
|
|
NZ336836A
(en)
|
1997-02-11 |
2001-02-23 |
Pfizer |
Arylsulfonyl hydroxamic acid derivatives suitable for a broad range of medicinal treatments
|
|
CA2289102A1
(en)
|
1997-05-07 |
1998-11-12 |
Sugen, Inc. |
2-indolinone derivatives as modulators of protein kinase activity
|
|
CA2291709A1
(en)
|
1997-05-30 |
1998-12-03 |
Merck & Co., Inc. |
Novel angiogenesis inhibitors
|
|
TR200000368T2
(tr)
|
1997-08-08 |
2000-07-21 |
Pfizer Products Inc. |
Ariloksiariarilsülfonilamino hidroksamik asit türevleri.
|
|
DE69838172T2
(de)
|
1997-08-22 |
2008-04-10 |
Astrazeneca Ab |
Oxindolylchinazolinderivate als angiogenesehemmer
|
|
AU744939B2
(en)
|
1997-09-26 |
2002-03-07 |
Merck & Co., Inc. |
Novel angiogenesis inhibitors
|
|
SK6652000A3
(en)
|
1997-11-11 |
2002-05-09 |
Pfizer Prod Inc |
Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
|
|
GB9725782D0
(en)
|
1997-12-05 |
1998-02-04 |
Pfizer Ltd |
Therapeutic agents
|
|
RS49779B
(sr)
|
1998-01-12 |
2008-06-05 |
Glaxo Group Limited, |
Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
|
|
GB9800575D0
(en)
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
|
GB9801690D0
(en)
|
1998-01-27 |
1998-03-25 |
Pfizer Ltd |
Therapeutic agents
|
|
PA8469401A1
(es)
|
1998-04-10 |
2000-05-24 |
Pfizer Prod Inc |
Derivados biciclicos del acido hidroxamico
|
|
PA8469501A1
(es)
|
1998-04-10 |
2000-09-29 |
Pfizer Prod Inc |
Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
|
|
KR100743287B1
(ko)
|
1998-05-29 |
2007-07-26 |
수젠, 인크. |
피롤기로 치환된 2-인돌리논 단백질 인산화 효소 억제제
|
|
UA60365C2
(uk)
|
1998-06-04 |
2003-10-15 |
Пфайзер Продактс Інк. |
Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
|
|
EP1004578B1
(en)
|
1998-11-05 |
2004-02-25 |
Pfizer Products Inc. |
5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
|
|
JP2002532415A
(ja)
|
1998-12-16 |
2002-10-02 |
ワーナー−ランバート・カンパニー |
Mek阻害剤による関節炎の治療
|
|
UA71945C2
(en)
|
1999-01-27 |
2005-01-17 |
Pfizer Prod Inc |
Substituted bicyclic derivatives being used as anticancer agents
|
|
IL129299A0
(en)
|
1999-03-31 |
2000-02-17 |
Mor Research Applic Ltd |
Monoclonal antibodies antigens and diagnosis of malignant diseases
|
|
GB9912961D0
(en)
|
1999-06-03 |
1999-08-04 |
Pfizer Ltd |
Metalloprotease inhibitors
|
|
EP1081137A1
(en)
|
1999-08-12 |
2001-03-07 |
Pfizer Products Inc. |
Selective inhibitors of aggrecanase in osteoarthritis treatment
|
|
CA3016482A1
(en)
|
1999-11-30 |
2001-06-07 |
Mayo Foundation For Medical Education And Research |
B7-h1, a novel immunoregulatory molecule
|
|
JP2001172261A
(ja)
|
1999-12-20 |
2001-06-26 |
Mitsubishi Chemicals Corp |
ピラゾールカルボン酸アミド類、およびこれを有効成分とする殺虫、殺ダニ剤
|
|
HRP20020751B1
(hr)
|
2000-02-15 |
2011-01-31 |
Sugen |
Pirolom supstituirani 2-indolinoni kao inhibitori protein kinaze
|
|
AU7349801A
(en)
|
2000-07-19 |
2002-01-30 |
Warner Lambert Co |
Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
|
|
AU2001290912A1
(en)
|
2000-09-15 |
2002-03-26 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
|
US6660731B2
(en)
|
2000-09-15 |
2003-12-09 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
|
US6995162B2
(en)
|
2001-01-12 |
2006-02-07 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
|
JP2002363164A
(ja)
|
2001-04-06 |
2002-12-18 |
Mitsubishi Chemicals Corp |
ピラゾールカルボキサミド類、その中間体およびこれを有効成分とする有害生物防除剤
|
|
CN1511142A
(zh)
|
2001-04-06 |
2004-07-07 |
日本农药株式会社 |
吡唑酰胺衍生物及用于制备该衍生物的中间体、以该衍生物为活性成分的有害生物防治剂
|
|
EP1478648B1
(en)
|
2002-02-01 |
2014-04-30 |
ARIAD Pharmaceuticals, Inc. |
Phosphorus-containing compounds and uses thereof
|
|
WO2004078163A2
(en)
|
2003-02-28 |
2004-09-16 |
Transform Pharmaceuticals, Inc. |
Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
|
|
CA2478065C
(en)
|
2002-03-08 |
2013-01-08 |
Eisai Co. Ltd. |
Macrocyclic compounds useful as pharmaceuticals
|
|
SG2013013339A
(en)
|
2002-03-13 |
2014-12-30 |
Array Biopharma Inc |
N3 alkylated benzimidazole derivatives as mek inhibitors
|
|
IL149820A0
(en)
|
2002-05-23 |
2002-11-10 |
Curetech Ltd |
Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
|
|
DE60334303D1
(de)
|
2002-07-03 |
2010-11-04 |
Tasuku Honjo |
Immunpotenzierende zusammensetzungen
|
|
ES2367430T3
(es)
|
2002-12-23 |
2011-11-03 |
Wyeth Llc |
Anticuerpos contra pd-1 y sus usos.
|
|
US20070060589A1
(en)
|
2004-12-21 |
2007-03-15 |
Purandare Ashok V |
Inhibitors of protein arginine methyl transferases
|
|
MX2007012463A
(es)
|
2005-04-08 |
2007-11-07 |
Pfizer Prod Inc |
Heteroarilamidas[3.1.0]biciclicas como inhibidores del transporte de glicina de tipo i.
|
|
EP3530736A3
(en)
|
2005-05-09 |
2019-11-06 |
ONO Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
|
|
BRPI0609464A2
(pt)
|
2005-05-23 |
2010-04-13 |
Japan Tobacco Inc |
composto de pirazol e agente terapêutico para diabetes compreendendo o mesmo
|
|
KR101704734B1
(ko)
|
2005-07-01 |
2017-02-09 |
이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. |
예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
|
|
MX2008002114A
(es)
|
2005-07-21 |
2008-04-17 |
Ardea Biosciences Inc |
Inhibidores de n-(arilamino)-sulfonamida de mek.
|
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
|
US9244059B2
(en)
|
2007-04-30 |
2016-01-26 |
Immutep Parc Club Orsay |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
|
EP1987839A1
(en)
|
2007-04-30 |
2008-11-05 |
I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
|
PT2170959E
(pt)
|
2007-06-18 |
2014-01-07 |
Merck Sharp & Dohme |
Anticorpos para o receptor humano de morte programada pd-1
|
|
WO2009025781A1
(en)
|
2007-08-16 |
2009-02-26 |
Beth Israel Deaconess Medical Center |
Activators of pyruvate kinase m2 and methods of treating disease
|
|
JPWO2009028280A1
(ja)
|
2007-08-29 |
2010-11-25 |
三井化学アグロ株式会社 |
ピラゾールカルボン酸誘導体及びその製造方法、並びに殺菌剤
|
|
BRPI0816769A2
(pt)
|
2007-09-12 |
2016-11-29 |
Hoffmann La Roche |
combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso
|
|
EP2044949A1
(en)
|
2007-10-05 |
2009-04-08 |
Immutep |
Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
|
|
WO2009055730A1
(en)
|
2007-10-25 |
2009-04-30 |
Genentech, Inc. |
Process for making thienopyrimidine compounds
|
|
US8168757B2
(en)
|
2008-03-12 |
2012-05-01 |
Merck Sharp & Dohme Corp. |
PD-1 binding proteins
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
WO2010098788A2
(en)
|
2008-08-25 |
2010-09-02 |
Amplimmune, Inc. |
Pd-i antagonists and methods for treating infectious disease
|
|
AU2009290544B2
(en)
|
2008-09-12 |
2015-07-16 |
Oxford University Innovation Limited |
PD-1 specific antibodies and uses thereof
|
|
WO2010036959A2
(en)
|
2008-09-26 |
2010-04-01 |
Dana-Farber Cancer Institute |
Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
|
|
ES2620634T3
(es)
|
2008-10-09 |
2017-06-29 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Activadores de piruvato quinasa humana
|
|
US8637550B2
(en)
|
2008-11-17 |
2014-01-28 |
Boehringer Ingelheim International Gmbh |
Heteroaryl diamide compounds useful as MMP-13 inhibitors
|
|
MX356367B
(es)
|
2008-12-09 |
2018-05-25 |
Genentech Inc |
Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
|
|
JP5756457B2
(ja)
|
2009-04-06 |
2015-07-29 |
アジオス ファーマシューティカルズ, インコーポレイテッド |
ピルビン酸キナーゼm2調節剤、治療組成物および関連する使用方法
|
|
PL2427441T3
(pl)
|
2009-05-04 |
2017-06-30 |
Agios Pharmaceuticals, Inc. |
Aktywatory PKM2 do stosowania w leczeniu raka
|
|
US8349832B2
(en)
|
2009-09-02 |
2013-01-08 |
Canthera Therapeutics |
Compounds and compositions for treating cancer
|
|
EP3279215B1
(en)
|
2009-11-24 |
2020-02-12 |
MedImmune Limited |
Targeted binding agents against b7-h1
|
|
EP2504028A4
(en)
|
2009-11-24 |
2014-04-09 |
Amplimmune Inc |
SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
|
|
WO2011069298A1
(en)
|
2009-12-11 |
2011-06-16 |
F. Hoffmann-La Roche Ag |
Novel cyclopropane indolinone derivatives
|
|
CN102892786B
(zh)
|
2010-03-11 |
2016-03-16 |
Ucb医药有限公司 |
Pd-1抗体
|
|
CN103079644B
(zh)
|
2010-06-11 |
2017-02-15 |
协和发酵麒麟株式会社 |
抗tim‑3抗体
|
|
US9163087B2
(en)
|
2010-06-18 |
2015-10-20 |
The Brigham And Women's Hospital, Inc. |
Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
|
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
|
CN103269706B
(zh)
|
2010-09-30 |
2015-06-24 |
黄奇英 |
抗癌萃取物及化合物
|
|
WO2012056319A1
(en)
|
2010-10-27 |
2012-05-03 |
Dynamix Pharmaceuticals Ltd. |
Sulfonamides for the modulation of pkm2
|
|
US9221792B2
(en)
|
2010-12-17 |
2015-12-29 |
Agios Pharmaceuticals, Inc |
N-(4-(azetidine-1-carbonyl) phenyl)-(hetero-) arylsulfonamide derivatives as pyruvate kinase M2 (PMK2) modulators
|
|
WO2012088314A1
(en)
|
2010-12-21 |
2012-06-28 |
Agios Pharmaceuticals, Inc. |
Bicyclic pkm2 activators
|
|
TWI549947B
(zh)
|
2010-12-29 |
2016-09-21 |
阿吉歐斯製藥公司 |
治療化合物及組成物
|
|
EP2497775A1
(en)
|
2011-03-11 |
2012-09-12 |
Ruprecht-Karls-Universität Heidelberg |
Ferrocene-based compounds and their use as ROS regulating prodrugs
|
|
CA2833636A1
(en)
|
2011-04-20 |
2012-10-26 |
Amplimmune, Inc. |
Antibodies and other molecules that bind b7-h1 and pd-1
|
|
WO2012160447A1
(en)
|
2011-05-25 |
2012-11-29 |
Dynamix Pharmaceuticals Ltd. |
3, 5 -diphenyl- substituted pyrazolines for the treatment of cancer, proliferative, inflammatory or autoimmune diseases
|
|
WO2013006490A2
(en)
|
2011-07-01 |
2013-01-10 |
Cellerant Therapeutics, Inc. |
Antibodies that specifically bind to tim3
|
|
WO2013005157A1
(en)
|
2011-07-05 |
2013-01-10 |
Lupin Limited |
Sulfone derivatives and their use as pkm2 modulators for the treatment of cancer
|
|
US8686119B2
(en)
|
2011-07-24 |
2014-04-01 |
Curetech Ltd. |
Variants of humanized immunomodulatory monoclonal antibodies
|
|
BR112014012819B1
(pt)
|
2011-11-28 |
2022-08-16 |
Merck Patent Gmbh |
Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
|
|
US9175082B2
(en)
|
2012-05-31 |
2015-11-03 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind PD-L1
|
|
AR091649A1
(es)
|
2012-07-02 |
2015-02-18 |
Bristol Myers Squibb Co |
Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
|
|
CN111499755A
(zh)
|
2012-08-03 |
2020-08-07 |
丹娜法伯癌症研究院 |
抗-pd-l1和pd-l2双结合抗体单一试剂及其使用方法
|
|
BR112015007672A2
(pt)
|
2012-10-04 |
2017-08-08 |
Dana Farber Cancer Inst Inc |
anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
|
|
EP2909181B1
(en)
*
|
2012-10-16 |
2017-08-09 |
Tolero Pharmaceuticals, Inc. |
Pkm2 modulators and methods for their use
|
|
NZ707778A
(en)
|
2012-11-08 |
2019-03-29 |
Agios Pharmaceuticals Inc |
Therapeutic compounds and compositions and their use as pkm2 modulators
|
|
AR093984A1
(es)
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
|
|
RS60538B1
(sr)
|
2013-03-15 |
2020-08-31 |
Glaxosmithkline Ip Dev Ltd |
Anti-lag-3 vezujući proteini
|
|
RS61400B1
(sr)
|
2013-05-02 |
2021-02-26 |
Anaptysbio Inc |
Antitela usmerena protiv programirane smrti-1 (pd-1)
|
|
CA3175360C
(en)
|
2013-05-31 |
2024-05-28 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind pd-1
|
|
WO2014209804A1
(en)
|
2013-06-24 |
2014-12-31 |
Biomed Valley Discoveries, Inc. |
Bispecific antibodies
|
|
WO2015021149A1
(en)
|
2013-08-06 |
2015-02-12 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Inhibitors of ack1/tnk2 tyrosine kinase
|
|
SMT202300039T1
(it)
|
2013-09-13 |
2023-03-17 |
Beigene Switzerland Gmbh |
Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
|
|
US10202454B2
(en)
|
2013-10-25 |
2019-02-12 |
Dana-Farber Cancer Institute, Inc. |
Anti-PD-L1 monoclonal antibodies and fragments thereof
|
|
WO2015081158A1
(en)
|
2013-11-26 |
2015-06-04 |
Bristol-Myers Squibb Company |
Method of treating hiv by disrupting pd-1/pd-l1 signaling
|
|
CR20160319A
(es)
|
2013-12-12 |
2016-11-08 |
Jiangsu Hengrui Medicine Co |
Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
|
|
LT3094351T
(lt)
|
2014-01-15 |
2022-04-11 |
Kadmon Corporation, Llc |
Imunitetą moduliuojantys agentai
|
|
US9447054B2
(en)
|
2014-01-15 |
2016-09-20 |
Korea Institute Of Radiological & Medical Sciences |
Anticancer supplement agent including benzo[D]oxazol derivative as effective ingredient
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對pd-1的人類抗體
|
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗pd-l1之人類抗體
|
|
UA122479C2
(uk)
|
2014-01-24 |
2020-11-25 |
Дана-Фарбер Кенсер Інстітьют, Інк. |
Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
|
|
WO2015116539A1
(en)
|
2014-01-28 |
2015-08-06 |
Bristol-Myers Squibb Company |
Anti-lag-3 antibodies to treat hematological malignancies
|
|
PL3099717T3
(pl)
|
2014-01-31 |
2019-10-31 |
Novartis Ag |
Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie
|
|
EA201691765A1
(ru)
|
2014-03-14 |
2016-12-30 |
Новартис Аг |
Молекулы антител против lag-3 и их применения
|
|
US9885721B2
(en)
|
2014-05-29 |
2018-02-06 |
Spring Bioscience Corporation |
PD-L1 antibodies and uses thereof
|
|
WO2015195163A1
(en)
|
2014-06-20 |
2015-12-23 |
R-Pharm Overseas, Inc. |
Pd-l1 antagonist fully human antibody
|
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
|
TWI726608B
(zh)
|
2014-07-03 |
2021-05-01 |
英屬開曼群島商百濟神州有限公司 |
抗pd-l1抗體及其作為治療及診斷之用途
|
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
|
SG11201702401RA
(en)
|
2014-10-14 |
2017-04-27 |
Novartis Ag |
Antibody molecules to pd-l1 and uses thereof
|
|
MY193661A
(en)
|
2014-11-06 |
2022-10-24 |
Hoffmann La Roche |
Anti-tim3 antibodies and methods of use
|
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗pd-1抗體類和使用彼等之方法
|
|
US20160200815A1
(en)
|
2015-01-05 |
2016-07-14 |
Jounce Therapeutics, Inc. |
Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
|
|
AU2016229189A1
(en)
|
2015-03-06 |
2017-09-21 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind TIM3
|
|
PL3277321T3
(pl)
|
2015-04-01 |
2024-11-18 |
Anaptysbio, Inc. |
Przeciwciała skierowane przeciwko białku 3 immunoglobuliny limfocytów t i mucyny (tim-3)
|
|
HUE045585T2
(hu)
|
2015-05-18 |
2020-01-28 |
Tolero Pharmaceuticals Inc |
Megnövelt biológiai hozzáférhetõséggel rendelkezõ Alvocidib gyógyszer-elõanyagok
|
|
US20180179282A1
(en)
*
|
2015-06-12 |
2018-06-28 |
Bristol-Myers Squibb Company |
Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways
|
|
EP3328496A4
(en)
|
2015-08-02 |
2018-12-19 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Inhibitors of ack1/tnk2 tyrosine kinase
|
|
JOP20190281A1
(ar)
|
2017-06-13 |
2019-12-02 |
Korea Res Inst Chemical Tech |
مشتق n2، n4 ثنائي فينيل بيريميدين -2، 4- ثنائي أمين، وطريقة لتحضيره، وتركيبة صيدلانية تحتوي على المشتق بوصفه مكون فعال للوقاية من السرطان أو علاجه
|
|
US20200237766A1
(en)
|
2017-10-13 |
2020-07-30 |
Tolero Pharmaceuticals, Inc. |
Pkm2 activators in combination with reactive oxygen species for treatment of cancer
|
|
AU2020245437A1
(en)
|
2019-03-22 |
2021-09-30 |
Sumitomo Pharma Oncology, Inc. |
Compositions comprising PKM2 modulators and methods of treatment using the same
|
|
JP2022527451A
(ja)
|
2019-03-22 |
2022-06-02 |
スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド |
Pkm2モジュレーターおよびその使用方法
|
|
AU2020300619A1
(en)
|
2019-07-03 |
2022-01-27 |
Sumitomo Pharma Oncology, Inc. |
Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
|